(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success ...

The designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

SOURCE: Biolog, Inc. The post Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

The European drug authority recommends refusal of marketing authorization due to evidence gaps in quality and efficacy.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, KalVista ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, Ionis ...